机译:跨膜激活剂,钙调节剂和亲环素配体相互作用物(TACI)中具有C104R突变的家庭成员的临床变异性
Department of Virology and Immunology Auckland City Hospital">(1);
Department of Molecular Medicine and Pathology University of Auckland">(2);
Department of Virology and Immunology Auckland City Hospital">(1);
Department of Molecular Medicine and Pathology University of Auckland">(2);
Maurice Wilkins Centre University of Auckland">(3);
School of Biological Sciences University of Auckland">(4);
Maurice Wilkins Centre University of Auckland">(3);
School of Biological Sciences University of Auckland">(4);
Department of Molecular Medicine and Pathology University of Auckland">(2);
Department of Virology and Immunology Auckland City Hospital">(1);
Department of Molecular Medicine and Pathology University of Auckland">(2);
Department of Clinical Immunology Auckland City Hospital">(5);
CVID; C104R mutation; infection; TACI;
机译:跨膜激活剂,钙调节剂和亲环蛋白配体相互作用物(TACI)中具有C104R突变的家庭成员的临床变异性。
机译:C104R突变体通过单倍体不足而损害跨膜激活剂,钙调节剂和亲环素配体相互作用物(TACI)的功能。
机译:跨膜激活剂和钙调节亲环素配体相互作用物(TACI)突变与常见的可变免疫缺陷相关的功能分析。
机译:将适应性突变和家族竞争与差异进化相结合,实现灵活的配体对接
机译:人B细胞跨膜激活剂和亲环蛋白配体相互作用物(TACI)的同工型的研究。
机译:C104R突变体通过HAPLONSUBCY损害跨膜活化剂和钙调制和钙调味剂和环孔配体交流剂(TACI)的功能
机译:C104R突变体通过HAPLONSUBCY损害跨膜活化剂和钙调制和钙调味剂和环孔配体交流剂(TACI)的功能
机译:检测新型TNF分泌配体的临床相关性和治疗潜力